Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial

Bibliography

• van Kerkhoven LA, Eikendal T, Laheij RJ, et al. Gastrointestinal symptoms are still common in a general Western population. Neth J Med 2008;66:18-22
   PubMed Web of Science ®Google Scholar
• Moser G. Functional gastrointestinal disorders. Wien Med Wochenschr 2006;156:435-40
   PubMedGoogle Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90
   PubMed Web of Science ®Google Scholar
• FAO and WHO. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ont. Canada; 2002
   Google Scholar
• Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503-14
   PubMed Web of Science ®Google Scholar
• LERCHE M, REUTER G. [A contribution to the method of isolation and differentiation of aerobic "lactobacilli" (Genus "Lactobacillus Beijerinck")]. Zentralbl Bakteriol 1960;179:354-70
   PubMedGoogle Scholar
• Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68
   PubMed Web of Science ®Google Scholar
• Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 2010;157:598-602
   PubMed Web of Science ®Google Scholar
• Cimperman L, Bayless G, Best K, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 2011;45:785-9
   PubMed Web of Science ®Google Scholar
• Shornikova AV, Casas IA, Mykkanen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-7
   PubMed Web of Science ®Google Scholar
• Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399-404
   PubMed Web of Science ®Google Scholar
• Francavilla R, Lionetti E, Castellaneta SP, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 2008;13:127-34
   PubMed Web of Science ®Google Scholar
• Imase K, Tanaka A, Tokunaga K, et al. Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi 2007;81:387-93
   PubMedGoogle Scholar
• Lionetti E, Miniello VL, Castellaneta SP, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-8
   PubMed Web of Science ®Google Scholar
• Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G1087-96
   PubMed Web of Science ®Google Scholar
• Branton WB, Jones ML, Tomaro-Duchesneau C, et al. In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int J Probiotics Prebiotics 2011;6:1-12
   Google Scholar
• Shimotoyodome A, Meguro S, Hase T, et al. Decreased colonic mucus in rats with loperamide-induced constipation. Comp Biochem Physiol A Mol Integr Physiol 2000;126:203-12
   PubMed Web of Science ®Google Scholar
• Klinkspoor JH, Mok KS, Van Klinken BJ, et al. Mucin secretion by the human colon cell line LS174T is regulated by bile salts. Glycobiology 1999;9:13-19
   PubMed Web of Science ®Google Scholar
• Lepercq P, Relano P, Cayuela C, Juste C. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol 2004;39:1266-71
   PubMed Web of Science ®Google Scholar
• Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002;16:587-93
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Jones ML, Martoni CJ, Prakash S. Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut 2013;62:654-5
   Google Scholar
• Jones ML, Martoni CJ, Tamber S, et al. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2012;50:2216-23
   PubMed Web of Science ®Google Scholar
• Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 2012;66:1234-41
   PubMed Web of Science ®Google Scholar
• Jones ML, Martoni CJ, Di PE, et al. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharmacol 2012;63:313-20
   PubMed Web of Science ®Google Scholar
• Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 2012;107:1505-13
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Tardino VM. A blueprint for symptom scales and responses: measurement and reporting. Gut 2004;53 Suppl 4:iv45-8
   PubMedGoogle Scholar
• Rome Foundation. Guidelines–Rome III diagnostic criteria for functional Gastrointestinal disorders. J Gastrointestin Liver Dis 2006;15:307-12
   PubMedGoogle Scholar
• Scaldaferri F, Pizzoferrato M, Pecere S, et al. Bacterial flora as a cause or treatment of chronic diarrhea. Gastroenterol Clin North Am 2012;41:581-602
   PubMed Web of Science ®Google Scholar
• Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011;45 Suppl:S149-53
   PubMed Web of Science ®Google Scholar
• Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009;15:300-10
   PubMed Web of Science ®Google Scholar
• Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286:G613-26
   PubMed Web of Science ®Google Scholar
• Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:513-17
   PubMed Web of Science ®Google Scholar
• Chadwick VS, Gaginella TS, Carlson GL, et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979;94:661-74
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-72
   PubMed Web of Science ®Google Scholar
• Ogilvie LA, Jones BV. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 2012;61:1642-3
   PubMed Web of Science ®Google Scholar
• Bercik P, Collins SM, Verdu EF. Microbes and the gut-brain axis. Neurogastroenterol Motil 2012;24(5):405-13
   PubMed Web of Science ®Google Scholar
• Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011;141:599-609
   PubMed Web of Science ®Google Scholar
• Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-82
   PubMed Web of Science ®Google Scholar
• Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8
   PubMed Web of Science ®Google Scholar
• Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42 Suppl 17:41-7
   PubMed Web of Science ®Google Scholar
• Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51:1775-80
   PubMed Web of Science ®Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61
   PubMed Web of Science ®Google Scholar